| Turkish Journal of Cancer |
| 2003, Volume 33, Number 3, Page(s) 150-153 |
|
[ Summary ]
[ Full Text ]
[ PDF ]
|
| Reevaluation of baseline staging tests in breast cancer; what should be the standard? |
| MUSTAFA SAMUR1, HAKAN ŞAT BOZCUK1, ŞEYDA KARAVELİ2, ELİF PEŞTERELİ2, MUSTAFA ÖZDOĞAN1, MUSTAFA YILDIZ1, MEHMET ARTAÇ1, BURHAN SAVAŞ1 |
1Department of Internal Medicine, Division of Medical Oncology, Akdeniz University Medical School, Antalya-Turkey 2Department of Pathology, Akdeniz University Medical School, Antalya-Turkey |
There has been an ongoing debate on staging in breast
cancer. In this study, we evaluated the metastasis detection
rate with baseline staging of breast cancer after operation.
One hundred consecutive breast cancer patients were
evaluated with liver ultrasonography, chest X-ray and bone
scans. All patients were followed at least for 6 months. More
than one third of our patients belong to the high risk group
(axillary involvement >3). In 3 patients (3%) metastasis
were detected. Two of them (5,8%) were in the group with
pT4, N2 or N1 (N >3), one of them (2,7%) was in the group
with pT2-3N0-1 (N £3). There was no metastasis in patients
with pT1N0-1 (N £3). To detect one case of occult metastasis
2000 Î were spent. As a result, routine staging does not
have a major impact on individual adjuvant treatment
planning. We recommend routine staging only for patients
with pT4 or N1, (N >3) or N2 disease, and we do not
recommend staging for patients with pT1N0-1, (N £3)
positive nodes. Decision about staging of the patients with
pT2-3N0-1, (N £3) diseases should be individualized according
to patients' and doctors' preferences and economic
resources.
|
|
[ Summary ]
[ Full Text ]
[ PDF ]
|
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
|